NVST Stock Forecast & Price Target

Envista Holdings is positioned to benefit from a stronger innovation cycle and improving execution across its Specialty Products & Technologies franchise, where implants are regaining momentum and the S-Series has already reached 18% of Nobel implant sales in 2Q across North America and Europe, with management expecting it to become the predominantly sold Nobel implant. Its Spark aligner business adds a powerful margin lever, as cost per aligner has fallen 40% over the past three years and further automation, scale, and production optimization could drive additional gross margin expansion while supporting growth from geographic expansion and DSO penetration. The company also raised medium-term core revenue growth to 2-5%, adjusted EBITDA growth to 5-8%, and adjusted EPS growth to 7-11%, while reiterating 100% free cash flow conversion and leveraging a large installed base of about 450K units globally.

Envista Holdings is facing a bearish setup because China orthodontic channel de-stocking tied to VBP is already causing a $10M 3Q revenue drawdown and could create $30M-$45M of 2027 revenue risk, with a similar hit to profitability and $0.10-$0.20 EPS risk if offsets fall short. The concern is amplified by management’s assumption that the $1.4B debt stack may be refinanced in mid-27 at a 200bp higher rate, which would pressure earnings growth over the next couple years. Although pricing has contributed about $100M of revenue over the past three years, the outlook is skeptical that this can durably offset inflation, especially if pricing gains invite share loss or margin compression.